Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On March 13, 2025, Dr. Reddy’s Laboratories announced a nationwide recall in the U.S. of a batch of Levetiracetam in 0.75% Sodium Chloride Injection due to mislabeling. The infusion bags were incorrectly labeled, posing a risk of patients receiving double the intended dose, potentially leading to serious side effects. The recall affects products distributed between November 4 and November 6, 2024, and involves notifying distributors and customers to return the affected products. The recall is conducted with the knowledge of the U.S. FDA, and no adverse events have been reported so far.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company is committed to providing access to affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Its major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with significant markets in the USA, India, Russia & CIS countries, China, Brazil, and Europe.
YTD Price Performance: -20.04%
Average Trading Volume: 1,832,963
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $10.68B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.